Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EKTERLY vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ekterly is a tissue-selective estrogen receptor degrader (SERD) that binds to the estrogen receptor (ER) and induces conformational changes leading to ER degradation. It antagonizes ER-mediated gene transcription and signaling, thereby inhibiting ER-dependent breast cancer cell proliferation.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
10 mg orally once daily
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is 12 hours. Steady state reached within 2 days. Accumulation negligible with once-daily dosing.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Ekterly is primarily metabolized by CYP3A4 and UGT1A8/1A9, with minor contributions from CYP2C9 and CYP2C19.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal excretion accounts for 70% of elimination, with 30% hepatobiliary/fecal. Approximately 15% is excreted unchanged in urine; the remainder as glucuronide metabolites.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
92% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein.
Approximately 85-90% bound to serum albumin.
Vd is 0.3 L/kg (25 L in 70 kg adult), indicating distribution primarily in extracellular fluid. No extensive tissue binding.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral bioavailability is 85% (range 75-95%). Food does not significantly affect absorption.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
GFR 30-59 m L/min: 5 mg once daily; GFR <30 m L/min: not recommended
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Not established for patients <18 years
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment; monitor renal function
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
There is no black box warning for Ekterly.
None.
Hepatotoxicity: Monitor liver function tests prior to and during treatment; discontinue if significant transaminase elevation or jaundice occurs.,Gastrointestinal disorders: Severe nausea, vomiting, dyspepsia, and diarrhea; manage with antiemetics and supportive care.,Hypersensitivity reactions: including angioedema and anaphylaxis; discontinue if occur.,QT interval prolongation: Avoid use in patients with baseline QT prolongation or those on QT-prolonging drugs; monitor electrolytes.,Fetal harm: Can cause fetal harm; advise effective contraception in women of reproductive potential.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to Ekterly or any excipients,Pregnancy,Lactation,Severe hepatic impairment (Child-Pugh C)
Hypersensitivity to AURLUMYN or any of its components.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition increasing upadacitinib exposure. No other significant food interactions known.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Insufficient human data; animal studies show fetal toxicity at maternal toxic doses. First trimester: potential risk of malformations; second/third trimester: risk of fetal growth restriction and oligohydramnios. Avoid use unless benefit outweighs risk.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No human data; M/P ratio unknown. Drug likely excreted into breast milk due to low molecular weight. Use with caution, monitor infant for adverse effects.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No established dose adjustments in pregnancy. Increased plasma volume and renal clearance may reduce drug exposure; monitor clinical response and adjust empirically if needed.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
EKTERLY is a combination of upadacitinib and methotrexate for moderate-to-severe rheumatoid arthritis. Monitor for serious infections, thrombosis, and GI perforations. Check baseline and periodic lipids, LFTs, and CBC. Avoid use with strong CYP3A4 inhibitors or inducers.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take EKTERLY exactly as prescribed. Do not stop without consulting your doctor.,Report any signs of infection, such as fever, cough, or skin redness, immediately.,Avoid live vaccines while taking EKTERLY. Update vaccinations before starting treatment.,Inform your doctor if you have a history of blood clots, stomach ulcers, or diverticulitis.,Use effective contraception during treatment and for at least 4 weeks after stopping.,Avoid grapefruit and grapefruit juice as they may increase side effects.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EKTERLY vs AURLUMYN, answered by our medical review team.
EKTERLY is a Antineoplastic Agent that works by Ekterly is a tissue-selective estrogen receptor degrader (SERD) that binds to the estrogen receptor (ER) and induces conformational changes leading to ER degradation. It antagonizes ER-mediated gene transcription and signaling, thereby inhibiting ER-dependent breast cancer cell proliferation.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EKTERLY and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EKTERLY is: 10 mg orally once daily. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EKTERLY and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EKTERLY is classified as Category C. Insufficient human data; animal studies show fetal toxicity at maternal toxic doses. First trimester: potential risk of malformations; second/third trimester: risk of fetal growth . AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.